Stock comparison

JAZZvsRPRX

Jazz Pharmaceuticals PLCvsRoyalty Pharma PLC. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

JAZZ

Jazz Pharmaceuticals PLC

$199.96

+17.95%

Pharmaceuticals$11.5BNASDAQ

RPRX

Royalty Pharma PLC

$49.64

+29.34%

Pharmaceuticals$27.1BNASDAQ

60-day price, rebased to 100

JAZZ +21.94% · RPRX +19.10%

Round-by-round

JAZZ 2·RPRX 3· 1tie

EdgeJAZZ

Valuation upside

-5.90% vs -57.50% to DCF fair value

EdgeRPRX

Balance-sheet strength

Altman Z 1.73 vs 2.25

Tie

Fundamental quality

Piotroski 5.00 vs 5.00 (of 9)

EdgeRPRX

Growth + margins

Rule-of-40 31.70 vs 109.80

EdgeJAZZ

60-day momentum

+21.94% vs +19.10% price return

EdgeRPRX

Market-cap liquidity

$11.5B vs $27.1B

Verdict

Across6categories,RPRXtakes the edge with3wins to2 (and 1 tie). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onJAZZorRPRX

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.